LIFECORE BIOMEDICAL, INC. Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
LIFECORE BIOMEDICAL, INC. (LFCR) reported Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $0 for the 7-month period ending 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-05-25 was $0.00.
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-02-23 was $0.00.
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-11-24 was $2.13M.
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-05-26 was $0.00.
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for fiscal 2025 was $2.13M.
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for fiscal 2024 was $0.00.
| Period end | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 1 month | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 7 month | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-KT · filed 2026-03-16 | |||||
| 2025-06-30 | $0.00 10-KT · filed 2026-03-16 | |||||
| 2025-05-25 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $2.13M derived: sum of 3 quarters · filed 2026-03-16 | $2.13M 10-KT · filed 2026-03-16 | ||
| 2025-02-23 | $0.00 10-Q · filed 2025-04-03 | $2.13M derived: sum of 2 quarters · filed 2025-04-03 | $2.13M 10-Q · filed 2025-04-03 | |||
| 2024-12-31 | $2.13M 10-KT · filed 2026-03-16 | |||||
| 2024-11-24 | $2.13M 10-Q · filed 2025-01-02 | $2.13M 10-Q · filed 2025-01-02 | ||||
| 2024-05-26 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 10-KT · filed 2026-03-16 | ||
| 2024-02-25 | $0.00 10-Q · filed 2025-04-03 | $0.00 derived: sum of 2 quarters · filed 2025-04-03 | $0.00 10-Q · filed 2025-04-03 | |||
| 2023-11-26 | $0.00 10-Q · filed 2025-01-02 | $0.00 10-Q · filed 2025-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |